Prognostic value of 18F–choline PET/CT metabolic parameters in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Prognostic value of 18F–choline PET/CT metabolic parameters in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide
Authors
Keywords
TLA, FCH-PET/CT, Abiraterone, Enzalutamide, CRPC, Castration-resistant prostate cancer
Journal
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
Volume 45, Issue 3, Pages 348-354
Publisher
Springer Nature
Online
2017-11-06
DOI
10.1007/s00259-017-3866-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- TLG-S criteria are superior to both EORTC and PERCIST for predicting outcomes in patients with metastatic lung adenocarcinoma treated with erlotinib
- (2016) Kung-Chu Ho et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Prostate cancer
- (2016) Gerhardt Attard et al. LANCET
- Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer
- (2016) Howard I. Scher et al. JAMA Oncology
- Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone
- (2015) S Salvi et al. BRITISH JOURNAL OF CANCER
- 18F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide
- (2015) Ugo De Giorgi et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- 11C-Choline PET/CT in castration-resistant prostate cancer patients treated with docetaxel
- (2015) Francesco Ceci et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Early outcome prediction on 18F-fluorocholine PET/CT in metastatic castration-resistant prostate cancer patients treated with abiraterone
- (2015) Ugo De Giorgi et al. Oncotarget
- Prognosis Related to Metastatic Burden Measured by 18F-Fluorocholine PET/CT in Castration-Resistant Prostate Cancer
- (2014) S. A. Kwee et al. JOURNAL OF NUCLEAR MEDICINE
- Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
- (2014) Tomasz M. Beer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
- (2013) C. Parker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Exploring the potential of [11C]choline-PET/CT as a novel imaging biomarker for predicting early treatment response in prostate cancer
- (2013) Amarnath Challapalli et al. NUCLEAR MEDICINE COMMUNICATIONS
- International Variation in Prostate Cancer Incidence and Mortality Rates
- (2012) Melissa M. Center et al. EUROPEAN UROLOGY
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
- (2012) Howard I. Scher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
- (2012) Charles J. Ryan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abiraterone and Increased Survival in Metastatic Prostate Cancer
- (2011) Johann S. de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
- (2010) Johann Sebastian de Bono et al. LANCET
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Vaporization of prostates of 80mL using a potassium-titanyl-phosphate laser: midterm-results and comparison with prostates of
- (2008) Jesco Pfitzenmaier et al. BJU INTERNATIONAL
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now